No Data
No Data
Weekly Buzz: Last Short Week of Jan Sees Records, Trump Gives Orders
Wall Street Today: Market Pulls Back After Wild Week
Live Stock: First Week Down, Market Pulls Back a Hair After Records
Wall Street Today: S&P 500 Closes at Record, Trump Keeps Appearing on TV
Biogen's Higher Dose Spinraza Under Review by US and EU Regulators
Wedbush Maintains Biogen(BIIB.US) With Hold Rating, Cuts Target Price to $166
thoughtful Bat_8163 : Looks like BIIB has made the wrong bet on Alzheimer in the past decade. Hopefully they can come out of the big disappointment!
QMengColdJoke OP thoughtful Bat_8163 : A dilemma, if they only keep sales and production, pv of existing drug could double price. People want to earn more so invest more, but eventually will run out of luck in some day.